|
1
|
Duvnjak M, Lerotić I, Barsić N, Tomasić V,
Virović Jukić L and Velagić V: Pathogenesis and management issues
for non-alcoholic fatty liver disease. World J Gastroenterol.
13:4539–4550. 2007.PubMed/NCBI
|
|
2
|
Angulo P: Non-alcoholic fatty liver
disease. N Engl J Med. 346:1221–1231. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yeh MM and Brunt EM: Pathology of
non-alcoholic fatty liver disease. Am J Clin Pathol. 128:837–847.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Farrell GC and Larter CZ: Non-alcoholic
fatty liver disease: from steatosis to cirrhosis. Hepatology.
43:S99–S112. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Postic C and Girard J: The role of the
lipogenic pathway in the development of hepatic steatosis. Diabetes
Metab. 34:643–648. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ayyad C and Andersen T: Long-term efficacy
of dietary treatment of obesity: a systematic review of studies
published between 1931 and 1999. Obes Rev. 1:113–119. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xue L: Progress in the pharmacological
study of Chinese herbal drug: Polygonum cuspidatum. Zhongguo
Zhong Yao Za Zhi. 25:651–653. 2000.PubMed/NCBI
|
|
8
|
Luper S: A review of plants used in the
treatment of liver disease: part two. Altern Med Rev. 4:178–188.
1999.PubMed/NCBI
|
|
9
|
Kimura Y: Pharmacological studies on
resveratrol. Methods Find Exp Clin Pharmacol. 25:297–310. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang H, Dou C and Gu F: Advances in the
study on pharmacological actions of Polygonum cuspidatum
Sieb: clearing heat and detoxication. Zhong Yao Cai. 26:606–610.
2003.PubMed/NCBI
|
|
11
|
Huang ZS, Wang ZW, Liu MP, Zhong SQ, Li QM
and Rong XL: Protective effects of polydatin against CCl(4)-induced
injury to primarily cultured rat hepatocytes. World J
Gastroenterol. 5:41–44. 1999.PubMed/NCBI
|
|
12
|
Ji H, Zhang X, Du Y, Liu H, Li S and Li L:
Polydatin modulates inflammation by decreasing NF-κB activation and
oxidative stress by increasing Gli1, Ptch1, SOD1 expression and
ameliorates blood-brain barrier permeability for its
neuroprotective effect in pMCAO rat brain. Brain Res Bull.
87:50–59. 2012.PubMed/NCBI
|
|
13
|
Du J, Sun LN, Xing WW, et al:
Lipid-lowering effects of polydatin from Polygonum
cuspidatum in hyperlipidemic hamsters. Phytomedicine.
16:652–658. 2009. View Article : Google Scholar
|
|
14
|
Xing WW, Wu JZ, Jia M, Du J, Zhang H and
Qin LP: Effects of polydatin from Polygonum cuspidatum on
lipid profile in hyperlipidemic rabbits. Biomed Pharmacother.
63:457–462. 2009.
|
|
15
|
Zhang Q, Zhao Y, Zhang DB and Sun LJ:
Effect of Sinai san decoction on the development of non-alcoholic
steatohepatitis in rats. World J Gastroenterol. 11:1392–1395. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brunt EM, Janney CG, Di Bisceglie AM,
Neuschwander-Tetri BA and Bacon BR: Nonalcoholic steatohepatitis: a
proposal for grading and staging the histological lesions. Am J
Gastroenterol. 94:2467–2474. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Folch J, Lees M, Sloane and Starley GH: A
simple method for the isolation and purification of total lipids
from animal tissues. J Biol Chem. 226:497–509. 1957.
|
|
18
|
Bartlett GR: Phosphorous assay in column
chromatography. J Biol Chem. 234:466–468. 1959.PubMed/NCBI
|
|
19
|
Zhang Q and Tan Y: Nerve growth factor
augments neuronal responsiveness to noradrenaline in cultured
dorsal root ganglion neurons of rats. Neuroscience. 193:72–79.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang Q, Yao F, Raizada MK, O'Rourke ST
and Sun C: Apelin gene transfer into the rostral ventrolateral
medulla induces chronic blood pressure elevation in normotensive
rats. Circ Res. 104:1421–1428. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Diehl AM, Li ZP, Lin HZ and Yang SQ:
Cytokines and the pathogenesis of non-alcoholic steatohepatitis.
Gut. 54:303–306. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tilg H and Diehl AM: Cytokines in
alcoholic and nonalcoholic steatohepatitis. N Engl J Med.
343:1467–1476. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Crespo J, Cayon A, Fernandez-Gil P, et al:
Gene expression of tumor necrosis factor alpha and TNF-receptors,
p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology.
34:1158–1163. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Abiru S, Migita K, Maeda Y, et al: Serum
cytokine and soluble cytokine receptor levels in patients with
non-alcoholic steatohepatitis. Liver Int. 26:39–45. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Poniachik J, Csendes A, Diaz JC, et al:
Increased production of IL-1alpha and TNFalpha in
lipopolysaccharide-stimulated blood from obese patients with
non-alcoholic fatty liver disease. Cytokine. 33:252–257. 2006.
View Article : Google Scholar
|
|
26
|
Tomita K, Tamiya G, Ando S, et al: Tumour
necrosis factor alpha signaling through activation of Kupffer cells
plays an essential role in liver fibrosis of non-alcoholic
steatohepatitis in mice. Gut. 55:415–424. 2006. View Article : Google Scholar
|
|
27
|
Hui JM, Hodge A, Farrell GC, Kench JG,
Kriketos A and George J: Beyond insulin resistance in NASH:
TNF-alpha or adiponectin. Hepatology. 40:46–54. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lanzilli G, Cottarelli A, Nicotera G,
Guida S, Ravagnan G and Fuggetta MP: Anti-inflammatory effect of
resveratrol and polydatin by in vitro IL-17 modulation.
Inflammation. 35:240–248. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang X, Song R, Bian HN, Brunk UT, Zhao M
and Zhao KS: Polydatin protects arterial smooth muscle cells
against mitochondrial dysfunction and lysosomal destabilization
following hemorrhagic shock. Am J Physiol Regul Integr Comp
Physiol. Jan 25–2002.(Epub ahead of print).
|
|
30
|
Shimano H: Sterol regulatory
element-binding proteins (SREBPs): transcriptional regulators of
lipid synthetic genes. Prog Lipid Res. 40:439–452. 2001. View Article : Google Scholar
|
|
31
|
Raghow R, Yellaturu C, Deng X, Park EA and
Elam MB: SREBPs: the crossroads of physiological and pathological
lipid homeostasis. Trends Endocrinol Metab. 19:65–73. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yan D, Lehto M, Rasilainen L, et al:
Oxysterol binding protein induces upregulation of SREBP-1c and
enhances hepatic lipogenesis. Arterioscler Thromb Vasc Biol.
27:1108–1114. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yahagi N, Shimano H, Hasty AH, Matsuzaka
T, Ide T and Yoshikawa T: Absence of sterol regulatory
element-binding protein-1 (SREBP-1) ameliorates fatty livers but
not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol
Chem. 277:19353–19357. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shimomura I, Bashmakov Y and Horton JD:
Increased levels of nuclear SREBP-1c associated with fatty livers
in two mouse models of diabetes mellitus. J Biol Chem.
274:30028–30032. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ahmed MH and Byrne CD: Modulation of
sterol regulatory element binding proteins (SREBPs) as potential
treatments for non-alcoholic fatty liver disease (NAFLD). Drug
Discov Today. 12:740–747. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ntambi JM, Miyazaki M, Stoehr JP, et al:
Loss of stearoyl-CoA desaturase-1 function protects mice against
adiposity. Proc Natl Acad Sci USA. 99:11482–11486. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shrestha S, Ehlers SJ, Lee JY, Fernandez
ML and Koo SI: Dietary green tea extract lowers plasma and hepatic
triglycerides and decreases the expression of sterol regulatory
element-binding protein-1c mRNA and its responsive genes in
fructose-fed, ovariectomized rats. J Nutr. 139:640–645. 2009.
View Article : Google Scholar
|
|
38
|
Saltiel A and Kahn CR: Insulin signalling
and the regulation of glucose and lipid metabolism. Nature.
414:799–806. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Browning J and Horton J: Molecular
mediators of hepatic steatosis and liver injury. J Clin Invest.
114:147–152. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Utzschneider KM and Kahn SE: Review: the
role of insulin resistance in nonalcoholic fatty liver disease. J
Clin Endocrinol Metab. 91:4753–4761. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Previs SF, Withers DJ, Ren JM, White MF
and Shulman GI: Contrasting effects of IRS-1 versus IRS-2 gene
disruption on carbohydrate and lipid metabolism in vivo. J Biol
Chem. 275:38990–38994. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Samuel VT, Liu ZX, Qu X, et al: Mechanism
of hepatic insulin resistance in non-alcoholic fatty liver disease.
J Biol Chem. 279:32345–32353. 2004. View Article : Google Scholar : PubMed/NCBI
|
